Cargando…
Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors
Spontaneous tumors are a major cause of death in cats. Treatment of human tumors has progressed dramatically in the past decade, partly due to the success of immunotherapies using immune checkpoint inhibitors, such as anti-programmed death 1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies. However, l...
Autores principales: | Maekawa, Naoya, Konnai, Satoru, Asano, Yumie, Otsuka, Takumi, Aoki, Eri, Takeuchi, Hiroto, Kato, Yukinari, Kaneko, Mika K., Yamada, Shinji, Kagawa, Yumiko, Nishimura, Maki, Takagi, Satoshi, Deguchi, Tatsuya, Ohta, Hiroshi, Nakagawa, Takayuki, Suzuki, Yasuhiko, Okagawa, Tomohiro, Murata, Shiro, Ohashi, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879432/ https://www.ncbi.nlm.nih.gov/pubmed/36701405 http://dx.doi.org/10.1371/journal.pone.0281143 |
Ejemplares similares
-
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Maekawa, Naoya, et al.
Publicado: (2021) -
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
por: Maekawa, Naoya, et al.
Publicado: (2022) -
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
por: Maekawa, Naoya, et al.
Publicado: (2016) -
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma
por: Maekawa, Naoya, et al.
Publicado: (2017) -
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours
por: Maekawa, Naoya, et al.
Publicado: (2023)